Atsushi Nakagawa

InstitutionKobe City Medical Center General Hospital
AddressKobe
Japan
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 8 Covid-19 publications, with a maximum of 3 publications in May 2021
    All Publications
    Bar chart showing 218 publications over 20 distinct years, with a maximum of 21 publications in 2013
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I, Hirai Y, Fujiwara S, Komase Y, Saraya T, Koh H, Kagiyama N, Shimada M, Kanou D, Antoku S, Uchida Y, Tokue Y, Takamori M, Gon Y, Ie K, Yamazaki Y, Harada K, Miyao N, Naka T, Iwata M, Nakagawa A, Hiyama K, Ogawa Y, Shinoda M, Ota S, Hirouchi T, Terada J, Kawano S, Ogura T, Sakurai T, Matsumoto Y, Kunishima H, Kobayashi O, Iwata S. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021 Dec; 10(4):2489-2509. PMID: 34453234.
      Citations: 3     
    2. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Fukushima S, Tomii K, Hashida T. Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2021 10; 10(10):1161-1170. PMID: 34292670.
      Citations: 1     Fields:    Translation:Humans
    3. Hasegawa T, Nakagawa A, Suzuki K, Yamashita K, Yamashita S, Iwanaga N, Tamada E, Noda K, Tomii K. Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19. Cytokine. 2021 12; 148:155618. PMID: 34127355.
      Citations:    Fields:    Translation:Humans
    4. Oi I, Ito I, Hirabayashi M, Endo K, Emura M, Kojima T, Tsukao H, Tomii K, Nakagawa A, Otsuka K, Akai M, Oi M, Sugita T, Fukui M, Inoue D, Hasegawa Y, Takahashi K, Yasui H, Fujita K, Ishida T, Ito A, Kita H, Kaji Y, Tsuchiya M, Tomioka H, Yamada T, Terada S, Nakaji H, Hamao N, Shirata M, Nishioka K, Yamazoe M, Shiraishi Y, Ogimoto T, Hosoya K, Ajimizu H, Shima H, Matsumoto H, Tanabe N, Hirai T. Pneumonia Caused by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Virus: A Multicenter Comparative Study. Open Forum Infect Dis. 2021 Jul; 8(7):ofab282. PMID: 34291119.
      Citations:    
    5. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021 06 24; 184(13):3452-3466.e18. PMID: 34139176.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    6. Ikeda S, Misumi T, Izumi S, Sakamoto K, Nishimura N, Ro S, Fukunaga K, Okamori S, Tachikawa N, Miyata N, Shinkai M, Shinoda M, Miyazaki Y, Iijima Y, Izumo T, Inomata M, Okamoto M, Yamaguchi T, Iwabuchi K, Masuda M, Takoi H, Oyamada Y, Fujitani S, Mineshita M, Ishii H, Nakagawa A, Yamaguchi N, Hibino M, Tsushima K, Nagai T, Ishikawa S, Ishikawa N, Kondoh Y, Yamazaki Y, Gocho K, Nishizawa T, Tsuzuku A, Yagi K, Shindo Y, Takeda Y, Yamanaka T, Ogura T. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study. Sci Rep. 2021 05 21; 11(1):10727. PMID: 34021229.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother. 2020 11 17; 64(12). PMID: 32958718.
      Citations: 41     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    8. Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H, Muroi N, Tomii K, Hashida T. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clin Transl Sci. 2020 09; 13(5):880-885. PMID: 32475019.
      Citations: 17     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    9. Teruya K, Hattori Y, Shimamoto Y, Kobayashi K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold. Biopolymers. 2016 Nov 04; 106(4):391-403. PMID: 26572934.
      Citations: 1     Fields:    Translation:Cells
    10. Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Bioorg Med Chem. 2015 Feb 15; 23(4):876-90. PMID: 25614110.
      Citations: 32     Fields:    Translation:HumansCells